In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Zivo Bioscience (ZIVO – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $3.28.
According to TipRanks, Vendetti is an analyst with an average return of -2.1% and a 29.66% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Cutera, Nuwellis, and Helius Medical Technologies.
Currently, the analyst consensus on Zivo Bioscience is a Moderate Buy with an average price target of $6.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.60 and a one-year low of $2.16. Currently, Zivo Bioscience has an average volume of 12K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zivo Bioscience, Inc. is engages in the study, development and commercialization of natural nutritional compounds and bioactive molecules from its proprietary algal strains. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.
Read More on ZIVO:
